HIV inhibiting pyrimidines derivatives
Details for Australian Patent Application No. 2002329238 (hide)
International Classifications
Event Publications
30 January 2003 Complete Application Filed
Priority application(s): 02077748.8 10.06.02 EP; 01203090.4 13.08.01 EP
29 May 2003 Application Open to Public Inspection
Published as AU-B-2002329238
24 January 2008 Application Accepted
Published as AU-B-2002329238
17 April 2008 Application for Amendment
The nature of the amendment is as shown in the statement(s) filed 27 Mar 2008. Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000
22 May 2008 Standard Patent Sealed
28 August 2008 Amendment Made
The nature of the amendment is as shown in the statement(s) filed 27 Mar 2008
12 July 2012 Extension of Term of Standard Patents
Janssen Pharmaceutica N.V. The earliest first regulatory approval date provided by the patentee 23 Dec 2011 For the goods EDURANT rilpivirine Address for service in Australia: Shelston IP Level 21 60 Margaret Street Sydney NSW 2000
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser